Epithelial ovarian cancer cell lines spontaneously derived from high-grade serious tumors
| Inventor | Institute |
|---|---|
| Anne-Marie Mes-Masson and Diane Provencher | Centre Hospitalier de Luniversité de Montréal |
| SKU: | 161780 |
|---|---|
| Product description: | Epithelial ovarian cancer cell lines spontaneously derived from high-grade serious tumors of patient who was treated with chemotherapy before collection due to recurring disease. Cell line was derived from rare case of HGS EOC where a somatic TP53 mutation was not detected by mutation screening. However, the absense of p53 mRNA and protein in addition to impaired p53 function was detected in this line. Therefore, this cell line has features characteristic of a p53-null mutation. It is suggested that in this cell line, TP53 regulation occurs at the mRNA level rather than protein level. |
| Alternate name: | TOV-3041G |
| Gender: | Female |
| CRISPR: | No |
| Production details: | Established using the Scrape method where tumor tissue was scraped into a 100mm plate with complete OSE medium and maintained for 40 days with medium replaced weekly. |
| Additional notes: | Patient 3041 was age 61 at diagnosis, BRCA hereditary status was negative, and disease stage was IVA. First line treatment was carboplatin/taxol, then sugery, followed by Cisplatin/taxol. Patient had no prior personal history of cancer but was part of a breast cancer prevention trial of tamoxifen previously. Year of sampling was 2007. |
| Receptors of note: | No |
| Cat. #: | 161780 |
|---|---|
| Cancer types: | Ovarian cancer |
| Research Fields: | Cancer |
| Organism: | Human |
| Tissue: | Derived from high-grade serous tumors |
| Gender: | Female |
| Morphology: | Small epithelial type cells and consistently formed compact spheroids |
| Growth properties: | Adherent |
| Primary citation: | Fleury et al. 2015. Genes & Cancer. 6(9-10):378-398. PMID: 26622941 |
| Shipping conditions: | Dry Ice |
|---|---|
| Growth medium: | OSE medium contains 10% FBS, 0.5ug/mL amphotericin B and 50 ug/mL gentamicin |
| Atmosphere: | Low oxygen conditions of 7% O2 and 5% CO2 |
| References: |
Vias et al. 2023. Elife. 11 12:e83867. PMID: 37166279 Sevinyan et al. 2022. Cancers (Basel). 16 14(22):5628. PMID: 36428724 Asare-Werehene et al. 2023. Cancers (Basel). 30 15(9):2566. PMID: 37174032 |
|---|
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.